Lucid Diagnostics appoints John R. Palumbo to Board of Directors.

Lucid Diagnostics has appointed John R. Palumbo to its Board of Directors, bringing 40 years of healthcare leadership experience to the table. Palumbo's background spans early-stage ventures, growth-stage companies, and Fortune 100 corporations, and his expertise will be valuable as Lucid approaches commercial milestones. The appointment was announced by Lucid's Chairman and CEO, Lishan Aklog, who sees Palumbo's experience as a significant asset to the company.

Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has appointed John R. Palumbo to its Board of Directors. The appointment, effective September 22, 2025, brings 40 years of healthcare leadership experience to the company, as announced by Lucid's Chairman and CEO, Lishan Aklog Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors^[1].

Palumbo, a senior healthcare executive, has a career spanning early-stage ventures, growth companies, and Fortune 100 enterprises. He has launched two companies through IPOs, guided emerging firms to scale, and led major transformation initiatives at large, complex organizations. His most recent role was as Executive Chairman of ValueHealth, where he led the company through a recapitalization in 2018 and a strategic investment in 2022. Prior to that, he held senior executive roles at AmerisourceBergen Corporation (NYSE: ABC, now Cencora, Inc.), Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX), and I-trax, Inc. (now part of Premise Health Holding Corp.) Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors^[1].

Lucid Diagnostics is focused on the millions of patients with gastroesophageal reflux disease (GERD) at risk of developing esophageal precancer and cancer. The company's EsoGuard® Esophageal DNA Test, performed with the EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available tool designed to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk patients Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors^[1].

Aklog sees Palumbo's extensive experience as a significant asset to Lucid as the company approaches transformational commercial milestones. "John's vast experience and deep expertise, including guiding early-stage companies through commercial growth, will be of great value as we position the Company for long-term success," said Aklog. Palumbo, who is currently serving on the boards of PM Pediatrics, ivWatch, and Qless, and chairs the Advisory Board of Brado, an AI-driven engagement platform, is excited about the opportunity to contribute to Lucid's mission Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors^[1].

The appointment of Palumbo comes at a critical stage for Lucid Diagnostics, as it continues to navigate the challenges posed by the COVID-19 pandemic and the uncertainties inherent in research and development. The company's forward-looking statements, as outlined in its recent filings, include risks such as volatility in stock price, general economic conditions, and regulatory approvals Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors^[1].